

CD40Ig treatment results in allograft acceptance mediated by CD8⁺CD45RC^{low} T cells, IFN- γ , and indoleamine 2,3-dioxygenase

Carole Guillonneau, ... , Maria Cristina Cuturi, Ignacio Anegon

J Clin Invest. 2007;117(4):1096-1106. <https://doi.org/10.1172/JCI28801>.

Research Article

Immunology

Treatment with CD40Ig results in indefinite allograft survival in a complete MHC-mismatched heart allograft model in the rat. Here we show that serial second, third, and fourth adoptive transfers of total splenocytes from CD40Ig-treated recipients into secondary recipients led to indefinite donor-specific allograft acceptance. Purification of splenocyte subpopulations from CD40Ig-treated recipients demonstrated that only the adoptively transferred CD8⁺CD45RC^{low} subset resulted in donor-specific long-term survival, whereas CD8⁺CD45RC^{low} T cells from naive animals did not. Accepted grafts displayed increased indoleamine 2,3-dioxygenase (IDO) expression restricted in the graft to ECs. Coculture of donor ECs with CD8⁺CD45RC^{low} T cells purified from CD40Ig-treated animals resulted in donor-specific IDO expression dependent on IFN- γ . Neutralization of IFN- γ or IDO triggered acute allograft rejection in both CD40Ig-treated and adoptively transferred recipients. This study demonstrates for what we believe to be the first time that interference in CD40–CD40L interactions induces allospecific CD8⁺ Tregs that maintain allograft survival. CD8⁺CD45RC^{low} T cells act through IFN- γ production, which in turn induces IDO expression by graft ECs. Thus, donor alloantigen-specific CD8⁺ Tregs may promote local graft immune privilege through IDO expression.

Find the latest version:

<http://jci.me/28801-pdf>





CD40Ig treatment results in allograft acceptance mediated by CD8⁺CD45RC^{low} T cells, IFN- γ , and indoleamine 2,3-dioxygenase

Carole Guillonéau,¹ Marcelo Hill,¹ François-Xavier Hubert,¹ Elise Chiffolleau,¹ Caroline Hervé,¹ Xian-Liang Li,¹ Michèle Heslan,¹ Claire Usal,¹ Laurent Tesson,¹ Séverine Ménoret,¹ Abdelhadi Saoudi,² Brigitte Le Mauff,¹ Régis Josien,¹ Maria Cristina Cuturi,¹ and Ignacio Anegón¹

¹INSERM U643, Centre Hospitalier Universitaire de Nantes, Institut de Transplantation et de Recherche en Transplantation (ITERT), and Université de Nantes, Faculté de Médecine, Nantes, France. ²INSERM U563, Département Immunologie, Toulouse, France.

Treatment with CD40Ig results in indefinite allograft survival in a complete MHC-mismatched heart allograft model in the rat. Here we show that serial second, third, and fourth adoptive transfers of total splenocytes from CD40Ig-treated recipients into secondary recipients led to indefinite donor-specific allograft acceptance. Purification of splenocyte subpopulations from CD40Ig-treated recipients demonstrated that only the adoptively transferred CD8⁺CD45RC^{low} subset resulted in donor-specific long-term survival, whereas CD8⁺CD45RC^{low} T cells from naive animals did not. Accepted grafts displayed increased indoleamine 2,3-dioxygenase (IDO) expression restricted in the graft to ECs. Coculture of donor ECs with CD8⁺CD45RC^{low} T cells purified from CD40Ig-treated animals resulted in donor-specific IDO expression dependent on IFN- γ . Neutralization of IFN- γ or IDO triggered acute allograft rejection in both CD40Ig-treated and adoptively transferred recipients. This study demonstrates for what we believe to be the first time that interference in CD40–CD40 ligand (CD40–CD40L) interactions induces allospecific CD8⁺ Tregs that maintain allograft survival. CD8⁺CD45RC^{low} T cells act through IFN- γ production, which in turn induces IDO expression by graft ECs. Thus, donor alloantigen-specific CD8⁺ Tregs may promote local graft immune privilege through IDO expression.

Introduction

Organ transplantation would benefit from immunotherapeutic strategies that enable the development of transplantation tolerance (1). Tolerance of donor antigens would avoid or reduce the administration of immunosuppressors and would simultaneously reduce the incidence of chronic graft dysfunction.

Over the past few years, Tregs of different phenotypes capable of suppressing immune responses have been identified (reviewed in ref. 2). Although several CD4⁺ populations have been described as being Tregs, CD8⁺ Tregs have also been identified in different models (3–14). One example of CD8⁺ Tregs is the non-cytokine-secreting, CD8⁺CD28⁻ alloantigen-specific Treg, which interacts directly with DCs or ECs and renders them tolerogenic (4, 11). Recently, a new natural regulatory CD8⁺CD45RC^{low}Foxp3⁺ subset has also been characterized (3).

In certain cases, allogeneic tolerance can be maintained and perpetuated into subsequent recipients by multiple and successive adoptive transfer of CD4⁺ Tregs into naive hosts (1). This condition has been termed infectious tolerance and has until now only been described for CD4⁺ Tregs (1, 15, 16).

Nonstandard abbreviations used: AdCD40Ig, adenovirus encoding CD40Ig; Addl324, adenovirus dl324 (noncoding); BN, Brown-Norway; CD40L, CD40 ligand; CDR3, complementary determining region 3; DST, donor-specific blood transfusion; HO-1, heme oxygenase-1; IDO, indoleamine 2,3-dioxygenase; IP, infectious particles; 1-MT, 1-methyl tryptophan.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J. Clin. Invest.* 117:1096–1106 (2007). doi:10.1172/JCI28801.

Administration of anti-CD40L (17) or anti-CD40 (18) mAbs as well as administration of CD40Ig (19) are among the most efficient treatments available to obtain long-term organ allograft survival in animal models, but the mechanisms are still poorly understood (reviewed in ref. 20). Anti-CD40L mAb has been shown to induce CD4⁺ Tregs (21) and deplete activated T cells through Fc-dependent mechanisms (22) or apoptosis (23). Interaction of DCs and T cells in the absence of CD40–CD40L interactions results in cross-tolerization of CD8⁺ T cells against cognate antigens (24–26). Anti-CD40L mAbs have also been shown to induce regulatory cells with a DC and/or NK phenotype in a model of autoimmune diabetes (27). CD40–CD40 ligand (CD40–CD40L) interactions can affect immune responses and inflammation not only through immune cell interactions but also by modulating the function of ECs and platelets (20).

We previously reported that administration of CD40Ig through gene transfer led to indefinite allograft survival in a complete MHC-mismatched heart allograft model in the rat (19). The aim of the present work is to analyze the *in vivo* mechanisms underlying graft acceptance.

Here we demonstrate that CD40Ig-induced graft acceptance is mediated by alloantigen-specific CD8⁺CD45RC^{low} Tregs that were able to impose inhibition of acute rejection to naive T cells when they were successively adoptively transferred up to 4 times. This is the first description of manipulation of CD40–CD40L interactions that resulted in the generation of CD8⁺ Treg cells. We also provide evidence that IFN- γ is produced by CD8⁺CD45RC^{low} T cells and



Table 1
Cardiac allograft survival after serial adoptive cell transfers

Group		No. of splenocytes	n	Donor strain	Graft survival (d)
Add324	First adoptive transfer	200 × 10 ⁶	7	LEW.1W	10 ± 2
AdCD40Ig	First adoptive transfer	200 × 10 ⁶	3	LEW.1W	>120
		50 × 10 ⁶	8	LEW.1W	>120
	Second adoptive transfer	200 × 10 ⁶	1	LEW.1W	>120
		100 × 10 ⁶	2	LEW.1W	>120
		50 × 10 ⁶	6	LEW.1W	>120
	Third adoptive transfer	50 × 10 ⁶	2	LEW.1W	>120
Fourth adoptive transfer	50 × 10 ⁶	3	LEW.1W	>120	
AdCD40Ig	First adoptive transfer	200 × 10 ⁶	3	BN	9

LEW.1A recipients were sublethally irradiated (4.5 Gy) at day -1 and received heart allografts and i.v. injections of splenocytes at day 0. Graft survival was monitored by abdominal palpation.

that indoleamine 2,3-dioxygenase (IDO) plays a crucial role in suppression of graft rejection. Finally, we show that these CD8⁺ Tregs induce ECs from graft origin to produce IDO through IFN- γ .

Results

CD40Ig-induced long-term survival is serially transferable to naive recipients. To assess whether tolerogenic cells were involved in the long-term allograft survival induced by CD40Ig treatment, we performed adoptive cell transfer experiments using splenocytes from CD40Ig-treated recipients. In agreement with our previously published results (19), recipients that received fully MHC-discordant LEW.1W heart allografts transduced with an adenovirus encoding CD40Ig (AdCD40Ig) exhibited long-term allograft survival (>120 days in 93% of recipients), whereas all recipients of grafts transduced with the control noncoding adenovirus dl324 (Addl324), rejected their grafts rapidly (8 ± 0.8 days). The first adoptive transfer of 50 × 10⁶ and 200 × 10⁶ splenocytes from CD40Ig-treated long-term survivor recipients (collected at day 120 after transplantation) to naive syngeneic recipients resulted in long-term acceptance of all LEW.1W cardiac allografts (Table 1). Grafts were rejected (6.5 ± 0.3 days) by recipients that did not receive splenocytes or that received splenocytes from control adenovirus-treated recipients (rejection 10 ± 2 days) (Table 1). Third-party Brown-Norway (BN) hearts transplanted into recipients receiving splenocytes from CD40Ig-treated long-term survivors with a LEW.1W heart were also promptly rejected (9 days) (Table 1). Whereas CD40Ig-treated recipients displayed high levels of circulating CD40Ig at day 10 after transplantation (229 ± 113 μ g/ml), recipients of the first adoptive cell transfer had undetectable levels of CD40Ig (<0.02 ng/ml). Recipients with long-surviving grafts after adoptive cell transfer displayed a reduction by more than 90% of serum anti-LEW.1W alloantibodies (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI28801DS1) and a 51% reduction in splenocyte anti-donor CTL activity (Supplemental Figure 1B).

Second adoptive cell transfers of 50 × 10⁶ to 200 × 10⁶ splenocytes from CD40Ig-treated recipients into naive animals also resulted in long-term acceptance of allogeneic hearts in all recipients (Table 1). All subsequent (third and fourth) adoptive cell transfers into naive animals performed with 50 × 10⁶ splenocytes recovered 120 days after transplantation and adoptive cell transfer resulted in long-term cardiac survival (Table 1).

These results demonstrate that CD40Ig-treated recipients contain regulatory cells capable of transferring donor-specific trans-

plantation tolerance, defined as acceptance of a second first-party graft and rejection of a third-party one. This transplantation tolerance was infectious and acted through dominant suppression of antiallogeneic immune responses.

Transfer of graft acceptance is dependent on CD8⁺ T cells. Whereas transfer of total splenocytes from CD40Ig-treated recipients uniformly transferred tolerance, T cell or CD8 depletion from the splenocytes abrogated the tolerance transfer (rejection at 14.5 ± 3.5 and 11 ± 0.7 days, respectively) (Figure 1A). In contrast, transfer of CD4-

depleted or NK-depleted splenocytes resulted in indefinite graft survival (Figure 1A). To confirm these results, we adoptively transferred positively selected CD40Ig T cells, CD40Ig CD4⁺ T cells, and CD40Ig CD8⁺ T cells. Adoptive transfer of positively selected T cells and CD8⁺ T cells resulted in indefinite allograft survival in all recipients, whereas adoptive transfer of CD4⁺ T cells led to allograft rejection 15 days (Figure 1B). CD8⁺ T cells were routinely more than 97% TCR $\alpha\beta$ ⁺ and CD8 α ⁺ and less than 2% CD4⁺ or CD161⁺ (data not shown).

Moreover, *in vivo* depletion of CD8⁺ T cells resulted in allograft rejection in 50% of the recipients ($n = 12$, $P < 0.0001$ versus CD40Ig plus control mAb) (Figure 1C), confirming an important role for these cells in the establishment of tolerogenic mechanisms during CD40Ig treatment. This treatment induced a permanent and marked reduction in peripheral blood CD8 α ⁺ and CD8 β ⁺ cells as shown by flow cytometry analyses performed every 2 weeks (Supplemental Figure 2) and by histological analysis of rejected cardiac grafts that lacked infiltrating CD8 α ⁺ and CD8 β ⁺ cells (data not shown). Administration to CD40Ig-treated recipients of an anti-MHC class I monomorphic mAb abolished long-term allograft survival, indicating that recognition of MHC class I antigens by CD8⁺ cells was implicated in the effect of CD40Ig (Figure 1C). Together, these data demonstrate that CD40Ig-induced donor-specific allograft acceptance is mediated by CD8 T cells.

CD8⁺CD45RC^{low} T cells are the key regulators induced by CD40Ig treatment. It has recently been shown that the level of CD45RC expression on rat CD8⁺ T cells distinguishes 2 CD8⁺ subsets that differ in their cytokine profiles and function (3). The CD8⁺CD45RC^{low} subset has been shown to contain Tregs that inhibit graft versus host disease and mixed lymphocyte reactions. To evaluate the contribution of CD8⁺CD45RC^{low} T cells in CD8⁺-mediated tolerance after CD40Ig treatment, CD8⁺CD45RC^{low} T cells and CD8⁺CD45RC^{high} T cells were sorted to a purity of greater than 99% (Figure 2A) and adoptively transferred into naive graft recipients (Figure 2B). Adoptive transfer of 2.5 × 10⁶ CD8⁺CD45RC^{low} T cells from CD40Ig-treated donors into syngeneic recipients resulted in indefinite allograft survival, whereas transfer of the same number of CD8⁺CD45RC^{high} T cells failed to inhibit acute rejection (Figure 2B). Adoptive transfer of CD8⁺CD45RC^{low} T cells from naive nongrafted animals in the same conditions did not inhibit acute rejection (Figure 2B).

Thus, CD40Ig treatment functionally modified CD8⁺CD45RC^{low} T cells to induce indefinite allograft survival, since CD8⁺CD45RC^{high}




Figure 2

CD8⁺CD45RC^{low} T cells mediate transfer of transplantation tolerance after CD40Ig treatment. **(A)** CD8⁺CD45RC^{low} and CD8⁺CD45RC^{high} T cells were sorted to greater than 99% purity from spleens. **(B)** Cells were purified from naive, CD40Ig-treated, or adoptively transferred recipients 120 days after transplantation. A total of 2.5×10^6 cells of each cell population was injected i.v. the day of transplantation of LEW.1W hearts into naive LEW.1A recipients sublethally irradiated (4.5 Gy) at day -1. Graft survival was assessed by abdominal palpation of cardiac beating. Black line, CD8⁺CD45RC^{low} T cells from CD40Ig-treated animals ($n = 4$). Dotted line, CD8⁺CD45RC^{low} T cells from adoptively transferred animals ($n = 2$). Gray line, CD8⁺CD45RC^{high} T cells from CD40Ig-treated animals ($n = 4$). Dashed gray line, CD8⁺CD45RC^{low} T cells from naive animals ($n = 4$). $P < 0.01$ for CD8⁺CD45RC^{low} from CD40Ig-treated animals versus CD8⁺CD45RC^{high} and CD8⁺CD45RC^{low} from naive animals.

pared with syngeneic grafts, long-surviving grafts from CD40Ig-treated recipients displayed a 50- to 100-fold increase in *Foxp3* and *IDO* mRNA, a 5- to 10-fold increase in PIR-B (the rat homolog of human ILT4), *CTLA4*, *HO-1*, a trend toward an increase in IFN- γ ($P = 0.052$), and the *TCR* β -chain, *perforin*, and *IL-2*. No significant differences were observed for TGF- β , IL-6, or IL-10 (Figure 5A). Long-surviving grafts from adoptively transferred recipients showed 20- and 100-fold increased accumulation of IFN- γ and *IDO*, respectively (Supplemental Figure 4), indicating that mRNA accumulation for regulatory molecules was a specific tolerogenic phenomenon independent of adenoviral gene transfer into the graft.

Immunohistology analysis showed the presence of abundant CD8⁺ cells expressing IFN- γ in CD40Ig long-surviving grafts but not in syngeneic grafts (Figure 5B). Thus, long-surviving grafts display CD8⁺ IFN- γ ⁺ cells and increased expression of molecules with tolerogenic or antiinflammatory activities, such as PIR-B, HO-1 and *IDO*, that may create local tolerogenic mechanisms.

IFN- γ and IDO mediated the effects of CD40Ig and CD8⁺CD45RC^{low} T cells. To analyze the contribution of IFN- γ to CD40Ig-induced donor-specific allograft acceptance mediated by CD8⁺CD45RC^{low} T cells, we treated recipients with a neutralizing anti-IFN- γ mAb from the day of transplantation and CD8⁺CD45RC^{low} transfer. This treatment abrogated long-term allograft survival in 3 of 4 recipients (Figure 6A). The remaining cardiac graft displayed reduced beating strength (from +++ to +). Administration of anti-IFN- γ alone did not modify the kinetics of acute rejection (data not shown).

Since IFN- γ is a major stimulus for *IDO* expression (28) and *IDO* was among the genes with the highest expression in the graft, we evaluated the role of *IDO* by pharmacologically blocking its activity with 1-methyl tryptophan (1-MT). Administration of 1-MT from the day of transplantation together with CD40Ig treatment at day 0 or 120 after adoptive transfer of CD8⁺CD45RC^{low} T cells resulted in rapid graft rejection in the majority of treated animals (Figure 6A).

Western blot analysis showed higher amounts of *IDO* in grafts from CD40Ig-treated and adoptively transferred recipients compared with the amounts shown in syngeneic grafts (Figure 6B). Higher amounts of *IDO* were also found in spleen of transplanted rats treated with adoptively transferred cells compared with spleen of rats with rejected grafts (Supplemental Figure 5). Immunohistologic analysis showed that ECs were the main cellular source of *IDO* within the grafts (Figure 6C).

To prove that Tregs generated by CD40Ig treatment could induce ECs to produce *IDO*, we performed in vitro coculture of donor ECs with CD8⁺CD45RC^{low} or CD8⁺CD45RC^{high} T cells. *IDO* activity, as measured by kynurenine accumulation in the culture supernatant, was detected when ECs were cocultured with CD8⁺CD45RC^{low} but not CD8⁺CD45RC^{high} T cells (Figure 6D). Furthermore, induction of *IDO* expression by ECs was dependent on IFN- γ production by CD8⁺CD45RC^{low} T cells, since kynurenine production was abrogated upon neutralization of IFN- γ with an mAb (Figure 6D). Analysis of *IDO* mRNA accumulation in ECs confirmed induction of *IDO* expression by recombinant IFN- γ used as a positive control (data not shown) as well as by CD8⁺CD45RC^{low} but not CD8⁺CD45RC^{high} T cells (Figure 6E). CD8⁺CD45RC^{low} T cells from CD40Ig-treated animals only induced *IDO* expression in ECs from graft donor LEW.1W origin but not from syngeneic LEW.1A ECs (data not shown).

Therefore, *IDO* is necessary for both the early induction of long-term allograft survival by CD40Ig and for the maintenance phase of tolerance mediated by CD8⁺CD45RC^{low} T cells. Infectious tolerance by CD8⁺CD45RC^{low} T cells was also dependent on IFN- γ , and CD8⁺CD45RC^{low} T cells induced *IDO* in ECs through IFN- γ production.

IDO overexpression in the graft but not at a distant site inhibits allograft rejection. Since *IDO* expression in the graft was associated with prolonged survival, we generated a recombinant adenovirus coding for *IDO* and tested the effect of *IDO* overexpression in the graft or at a distant site such as the hind limb. When *IDO* gene transfer





Figure 3 Expression of IFN- γ and regulatory molecules by CD8⁺CD45RC^{low} T cells. **(A)** Intracytoplasmic analysis of IFN- γ production in total splenocytes and in CD8⁺CD45RC^{low} and CD8⁺CD45RC^{high} cells from CD40lg-treated or adoptively transferred animals. Cells were harvested, stimulated for 7 hours using phorbol myristate acetate and ionomycin, and analyzed with a FITC-labeled anti-IFN- γ mAb. Results are expressed as percent of positive cells. Each symbol indicates a value for an individual animals. Lines indicate mean \pm SD. ATS, adoptively transferred. * P < 0.05, ** P < 0.01, and *** P < 0.001. **(B)** Quantitative analysis of transcript accumulation was performed after isolation in CD8⁺CD45RC^{low} or CD8⁺CD45RC^{high} T cells isolated from CD40lg-treated recipients or in CD8⁺CD45RC^{low} cells from naive animals. Results are expressed in arbitrary units of molecules normalized to HPRT \pm SD. GITR, glucocorticoid-induced tumor necrosis factor receptor family-related gene. * P < 0.05, ** P < 0.01, and *** P < 0.001.

was performed in the graft, survival was significantly prolonged, with 45% of the grafts surviving more than 90 days, whereas survival was not significantly prolonged when gene transfer was performed in the hind limb (Figure 7). Although 1-MT blocks the effect of CTLA4Ig treatment in a model of islet allotransplanta-

tion in mice (29), administration of 1-MT to CTLA4Ig-treated rats did not result in graft rejection (Supplemental Figure 6), indicating that the effects on CD40lg-treated animals were specific. These results confirmed that IDO overexpression in the graft is sufficient to induce permanent allograft survival, and although

**Figure 4**

Analysis of the TCR repertoire in $CD8^+CD45RC^{low}$ T cells. $CD8^+CD45RC^{low}$ or $CD8^+CD45RC^{high}$ T cells were purified from spleen of CD40Ig-treated or naive animals. A qualitative and quantitative analysis of the TCR $V\beta$ transcriptome was performed as described in Methods. Each histogram represents a qualitative immunoscope analysis of the $V\beta$ 11 family repertoire of 1 animal. The histograms display the intensity of fluorescence in arbitrary units as a function of runoff CDR3 $V\beta$ 11 length in nucleotides. The CDR3 length distribution was unaltered (gaussian) in $CD8^+CD45RC^{low}$ from all naive animals or $CD8^+CD45RC^{high}$ from CD40Ig-treated recipients and altered (non-gaussian) in spleen $CD8^+CD45RC^{low}$ T cells from all CD40Ig-treated recipients with a predominant CDR3 of always the same length (27 nucleotides, arrows).

IDO gene transfer in the graft was less efficient than transfer of $CD8^+CD45RC^{low}$ T cells, this can be explained by a transient expression of IDO when using adenoviruses.

Discussion

The major findings of the current study were that long-term allograft survival induced by CD40Ig was dependent on $CD8^+CD45RC^{low}$ Tregs, that $IFN-\gamma$ and IDO were necessary for long-term allograft survival, and that interaction between $CD8^+CD45RC^{low}$ T cells and graft ECs possibly underlines these mechanisms. The allograft acceptance induced by CD40Ig treatment was obtained in a major MHC-mismatched cardiac allograft model, was able to be adoptively transferred by $CD8^+CD45RC^{low}$ T cells into euthymic transplanted recipients, and was donor specific.

Infectious allogeneic tolerance was first demonstrated in thymectomized mice treated with anti-CD4 and anti-CD8 mAbs, and tolerance was serially transferred using splenocytes or $CD4^+$ but not $CD8^+$ cells (1). The same group showed that anti-CD40L and anti-CD8 mAb treatment also resulted in infectious tolerance mediated by $CD4^+$ T cells (30). Infectious tolerance by $CD4^+$ T cells has also been described in rats following donor-specific blood transfusion (DST) (16) and anti-CD4 mAb treatment (15). In all these models, only $CD4^+$ T cells transferred tolerance or were much more potent than $CD8^+$ T cells (16). Thus, our model of CD40Ig treatment is the first in which infectious tolerance is mediated by $CD8^+$ T cells. Furthermore, the potency of these cells is high, since as few as 50×10^6 splenocytes or 2.5×10^6 $CD8^+CD45RC^{low}$ T cells were able to inhibit acute rejection in an MHC-incompatible strain combination for at least 4 generations without loss of efficacy. It is unclear why $CD4^+$ Tregs were absent in our model but predominate in mouse models using anti-CD40L mAbs. Some differences in these models, such as different molecules (CD40Ig versus anti-CD40L), the continuous presence of CD40Ig versus only inductive treatment with anti-CD40L, and the species used may explain this discrepancy. CD40Ig also induced indefinite survival of allogeneic livers (31), but the role of $CD4^+$ or $CD8^+$ Tregs was not analyzed. Anti-CD40L mAbs have been proposed to act at least in part through depletion of activated $CD4^+$ T cells (22, 23). Absolute numbers of $CD4^+$ T cells were decreased in CD40Ig-treated recipients compared with num-

bers of $CD4^+$ T cells in grafted untreated or adoptively transferred recipients but were comparable to those of naive animals (Supplemental Figure 7A). $CD8^+$, $CD8^+CD45RC^{low}$, and $CD4^+CD25^{high}$ T cells were not modified in CD40Ig-treated animals versus naive or control Add1324-treated recipients, whereas $CD8^+CD45RC^{low}$ T cells were increased in adoptively transferred recipients versus naive or CD40Ig-treated recipients. CD40Ig also had a differential effect in vitro in $CD4^+$ and $CD8^+$ T cells, since it showed higher inhibition of MLR responses by $CD4^+CD25^-$ naive T cells than $CD8^+CD45RC^{high}$ or $CD8^+CD45RC^{low}$ cells (Supplemental Figure 7B). These results suggest a specific differential effect of CD40Ig on $CD4^+$ T cells compared with $CD8^+$ T cells in grafted animals. This could be related to higher levels of CD40L expression on rat $CD4^+$ versus $CD8^+$ T cells (data not shown). These results also suggest that defective alloantigen presentation due to blockade of CD40-CD40L interactions and decrease of $CD4^+$ T cells may participate in the generation of $CD8^+CD45RC^{low}$ cells.

$CD8^+$ Tregs have been described in several models (3–14). In allotransplantation models, $CD8^+CD28^-$ Tregs were induced by in vitro allogeneic stimulation of human cells (11) or by DST treatment in rats (4). Induction of the immunoreceptor tyrosine-based inhibitory motifs-containing motifs ILT3 and ILT4 on human DCs (11) or of PIR-B on graft rat ECs (4) have been described. The $CD8^+Foxp3^+$ cells induced by DST did not produce $IFN-\gamma$ and were able to transfer tolerance in only 60% of primary recipients (4). Thus, the $CD8^+$ Tregs described in the present study could be a counterpart to the human $CD8^+CD28^-$ cells but are different from the ones described in DST-treated rats. $CD8^+$ T cells tolerogenic for alloantigens have also been described following oral exposure to alloantigens (5) or to DST treatment (13, 14, 16), but their phenotype or cytokine production was not analyzed further. Administration of agonistic anti-CD137 mAbs to mice to suppress autoimmune arthritis through the generation $CD8^+CD11c^+$ Tregs capable of producing $IFN-\gamma$ was recently described (8). DCs from these mice expressed IDO, and the tolerogenic effect of anti-CD137 mAb was abolished by treatment with anti- $IFN-\gamma$ or 1-MT. Thus, agonistic anti-CD137 and CD40Ig seem to generate similar mechanisms of tolerance acting through $CD8^+$ T cells, $IFN-\gamma$, and IDO. It remains to be determined which of the 2 costimulatory pathways is upstream of the




Figure 5

Grafts accepted long term after CD40Ig treatment showed strong accumulation of transcripts for regulatory molecules. Heart grafts from syngeneic donors or from allogeneic donors were harvested 120 days after transplantation. Recipients from allogeneic donors were treated with CD40Ig. (A) Heart total RNA was analyzed using real-time quantitative RT-PCR. Symbols indicate values for individual animals in arbitrary units. *P < 0.05, and **P < 0.01 versus syngeneic animals. (B) Confocal analysis of allogeneic or syngeneic (inserts) grafts using anti-CD8 α (red) or anti-IFN- γ (green) antibodies. Merge analysis shows IFN- γ expression almost exclusively restricted to CD8⁺ cells (arrows), whereas some cells are IFN- γ ⁻ (arrowheads). Identical results were obtained with 3 grafts from CD40Ig-treated animals and from adoptively transferred grafts. Original magnification, \times 400.

other in each model and whether certain phenotypic differences truly distinguish the different cell populations (CD8⁺CD45RC^{low} T cells are CD11c⁻). Finally, a population of naturally occurring CD8⁺CD45RC^{low} Tregs was recently described in the rat (3). In contrast to the lack of effect of these natural CD8⁺CD45RC^{low} cells in our cardiac transplantation model, CD40Ig-treated recipients showed CD8⁺CD45RC^{low} cells able to suppress graft rejection. This indicated that blockade of CD40 signals may have enabled an increase in suppressive function and/or expansion of alloantigen-specific T cells within naturally occurring CD8⁺CD45RC^{low} T cells, as described for natural versus induced CD4⁺ Tregs in the absence of CD40 signals (26) or following other treatments (32, 33). The presence of a restricted TCR V β 11 usage by CD8⁺CD45RC^{low} T cells from CD40Ig-treated recipients and not naive animals suggests the expansion of an antigen-specific population of cells. As previously reported for natural and induced CD4⁺ Tregs (33), transcript levels of several cytokines and markers (IL-10, IFN- γ , and Foxp3) were not significantly different in CD8⁺CD45RC^{low} T cells from CD40Ig-treated compared with naive animals. Nevertheless, for other molecules analyzed (GITR, TGF- β , IL-2, CD25, and CD28), there were significant differences, and a DNA microarray analysis has shown 127 genes differentially regulated between the 2 populations (B. Le Mauff and I. Anegon, unpublished observations).

Although induction of tolerance to alloantigens in vivo using anti-CD40L (34), or CD25⁺CD4⁺ Tregs (35) has also been shown

to require IFN- γ , the role in tolerance of downstream molecules regulated by IFN- γ , such as IDO, was not demonstrated. IFN- γ may act as a double-edged sword, since it may not only inhibit acute rejection but also promote chronic rejection (36). Thus, the production of IFN- γ might explain why most graft tolerance-promoting strategies, including those resulting in infectious tolerance, such as administration of anti-CD40L, result in simultaneous efficient inhibition of acute rejection and development of chronic rejection lesions (37).

Long-surviving grafts showed increased expression of mRNA for *PIR-B*, *HO-1*, and *IDO*. *PIR-B* is homologous to human *ILT4*, which is expressed by DCs and ECs and inhibits alloreactive T cell activation (4). *HO-1* is a tissue-protective gene which was shown to be necessary for tolerance induction in anti-CD40L and *DST* treatment (38), but its inhibition in our model by in vivo administration of tin-protoporphyrin did not abrogate CD40Ig-induced tolerance (data not shown).

IDO degrades tryptophan, which can be further degraded through the kynurenine pathway (28), and its activity can induce T cell apoptosis or anergy (28, 39). *IDO* can be produced by several cell types including DCs and ECs, and IFN- γ is a major stimulus of its functional expression (28, 40). Specific inhibition of *IDO* using 1-MT has been shown to abrogate tolerance in a number of models (8, 28, 29, 41). In all of these studies, *IDO* production was analyzed in DCs but not in other cell types, despite the fact that




Figure 6

IFN- γ and IDO mediate the effect of CD40lg and of CD8⁺CD45RC^{low} T cells. **(A)** Graft survival after 1-MT or anti-IFN- γ mAb administration beginning the day of transplantation (d0) to CD40lg-treated animals or to animals receiving adoptive transfers at 120 days after transplantation (d120). Heartbeat of nonrejected grafts after 1-MT or anti-IFN- γ administration was + compared with +++ in CD40lg-treated or adoptively transferred recipients. Arrow indicates adoptive transfer and beginning of treatment with 1-MT. **(B)** Representative Western blot analysis of IDO expression in cardiac grafts from syngeneic, CD40lg-treated, and adoptively transferred recipients at day 120. Histograms show quantification of IDO normalized to tubulin in 3–4 samples per group. ** $P < 0.01$, syngeneic versus adoptively transferred grafts. **(C)** Confocal analysis of grafts from adoptively transferred or syngeneic recipients using anti-IDO (green) and anti-CD31 (red) antibodies. Merge analysis shows IDO expression almost exclusively restricted to ECs. The inserts represent staining using an irrelevant mAb (3G8) or rabbit serum. Identical results were obtained with 2 other grafts from adoptively transferred animals and 2 grafts from CD40lg-treated animals. Original magnification, $\times 400$. **(D)** Kynurenine in cultured supernatants. CD8⁺CD45RC^{low} or CD8⁺CD45RC^{high} T cells from CD40lg-treated recipients ($n = 2$ in each group) were cultured for 2 days with ECs from LEW.1W animals in the presence of anti-IFN- γ or control mAb (3G8) at 20 $\mu\text{g/ml}$. Levels are expressed as $\mu\text{M} \pm \text{SD}$. * $P < 0.05$. **(E)** Quantitative RT-PCR analysis of IDO mRNA in ECs cultured for 2 days with CD8⁺CD45RC^{low} or CD8⁺CD45RC^{high} T cells from CD40lg-treated recipients ($n = 3$ in each group). ** $P < 0.01$ for CD8⁺CD45RC^{low} versus CD8⁺CD45RC^{high}.

ECs also express IDO (40). Our results demonstrate, for what we believe to be the first time, that IDO has a pivotal role in long-term allograft survival following manipulation of CD40-CD40L interactions. The present results also demonstrate for what we believe to be the first time that IDO can be produced by graft ECs and that Tregs can induce the expression of IDO in ECs. Nevertheless, since we have also documented increased IDO expression in spleens of CD40lg-treated animals, the relative role of graft ECs versus spleen cells producing IDO requires further study.

The activation of CD8⁺CD45RC^{low} T cells in CD40lg-treated animals is donor alloantigen-specific, since BN third-party grafts but not first-donor LEW.1W grafts were rejected upon adoptive transfer. Furthermore, $\text{V}\beta$ TCR repertoire alterations also indicate that

CD8⁺CD45RC^{low} T cell responses were selected and likely directed against donor MHC class I antigens, since anti-MHC class I mAb administration abrogated long-term graft survival. Further experiments are needed to define whether CD8⁺CD45RC^{low} T cells recognize MHC class Ia antigens or Ib molecules, as previously described for CD8⁺ Tregs in mice models of autoimmunity (6). Although triggering of CD8⁺CD45RC^{low} T cells was donor alloantigen specific, production of IFN- γ and IDO could theoretically result in the nonspecific inhibition of other concomitant immune responses. Nevertheless, we have previously shown that CD40lg-treated recipients show normal anticognate immune responses after CD40lg gene transfer at early and late time points after gene transfer (19). It is possible that activation of CD8⁺CD45RC^{low} T cells by




Figure 7

IDO gene transfer into the graft but not at a distant site results in long-term allograft survival. AdIDO or Addl324 (2×10^{10} IP) were injected into the cardiac grafts or intramuscularly into the hind limb the day of transplantation. Rejection was defined when beating of the transplanted heart could no longer be detected. $P < 0.001$, AdIDO graft versus Addl324 and AdIDO i.m.

graft ECs localizes the effects of IFN- γ and IDO to the graft. The localization and/or activation of Tregs in target tissues has been previously described in transplant (42) and autoimmune diabetes (43) models. As recently speculated, Tregs may act by inducing an immune privileged site through mechanisms similar to those occurring in natural immune privileged sites such as for IDO in the placenta (44). Alternatively, IFN- γ is directionally secreted into the immunological synapse, whereas other cytokines show multi-directional secretion (45). This could provide another mechanism for a limited effect even in lymphoid secondary organs.

DC-T cell interaction in the absence of CD40L-CD40 results in cross-tolerization of CD8⁺ T cells, whereas DC stimulation through CD40 results in T cell priming (24–26). When the role of IDO was analyzed, it was shown to be essential for cross-tolerization of CD8⁺ T cells by DCs (25). Thus, it is possible that in our model, CD40 blockade resulted in alloantigen presentation by DCs and/or ECs to CD8⁺ T cells in a tolerogenic manner through IDO expression.

In summary, we have provided in vivo evidence of a role for a CD8⁺CD45RC^{low} T cell population with tolerogenic properties following CD40Ig treatment. We have demonstrated that CD8⁺CD45RC^{low} T cells are capable of infectious allogeneic tolerance through dominant suppression by expression of IFN- γ , which in turn induces IDO expression.

Methods

Animals and cardiac allograft models. Eight- to 12-week-old male LEW.1W (haplotype RT1^u) and LEW. 1A (haplotype RT1^a) (Centre d’Elevage Janvier) differ in their entire MHC region. Heterotopic abdominal LEW.1W heart survival in LEW.1A recipients was evaluated by palpation through the abdominal wall and heart beating was graded from +++ to -. The experiments in animals were approved by the official French veterinarian authorities (Services Vétérinaires de la Loire Atlantique, La Chapelle-sur-Erdre, France).

CD40Ig or IDO gene transfer and mAb administration. The adenovirus AdCD40Ig coding for the extracellular portion of mouse CD40 fused to the coding sequences of the constant domains of human IgG1 and the non-coding vector Addl324 have been described previously (19). An adenovirus coding for IDO was constructed as previously described (46) and was confirmed to express enzymatically active IDO (data not shown). A total of 2×10^{10} adenovirus infectious particles (IP) was slowly injected at 3 points into the graft ventricular walls.

CD8⁺ cells were depleted by injecting 3 mg/kg of an anti-CD8 α mAb (OX8, IgG1) i.p. twice a week from day 0 until sacrifice (day 120).

A neutralizing mouse anti-rat IFN- γ mAb (hybridoma DB1, IgG1, kindly provided by P.H. Van der Meisle, Rijswijk, The Netherlands) or an anti-MHC class Ia and Ib mAb (OX18) (3 mg/kg) was injected i.p. twice a week from day 0 until rejection or day 40. An irrelevant isotype-matched mAb (anti-human CD16, clone 3G8, IgG1) was used as control.

Lymphocyte preparation, isolation or depletion of subpopulations, and adoptive transfer. Spleens were harvested 120 days after transplantation from recipients that had accepted their grafts long-term and from untreated recipients that had rejected their allografts at around day 7.

Cell transfers were performed by i.v. injection of total splenocytes or purified splenocyte subpopulations on the day of transplantation into LEW.1A recipients sublethally irradiated (4.5 Gy whole-body irradiation) 1 day earlier.

For adoptive cell transfer of splenocytes depleted of different leukocyte subpopulations, 50×10^6 splenocytes were depleted of T cells, CD4⁺ cells, CD8⁺ cells, MHC class II⁺ cells, and NK⁺ cells using negative selection with anti-TCR $\alpha\beta$ (R.7.3), anti-CD4 (W3.25), anti-CD8 α , anti-MHC class II (OX6), and anti-CD161 (NKR-P1A, 3.2.3), followed by incubation with anti-mouse IgG-coated magnetic beads (Dynal). Cells remaining after depletion of the different cell populations contained less than 1% of contaminating cells and were injected i.v.

For adoptive cell transfer of purified splenocyte subpopulations, cells were isolated by negative selection. T cells were isolated by nylon wool adherence, and depletion of non-T cells was performed with a mixture of anti-CD161, anti-CD11b/c (OX42), anti-CD45R (His 24), and anti-Igk chain (OX12) and incubation with anti-mouse IgG-coated beads. CD8⁺ or CD4⁺ T cells were purified using this cocktail of mAbs including an anti-CD4 mAb or an anti-CD8 α mAb, respectively. Purity of all these subpopulations was routinely greater than 95%. The number of cells of each population injected, either depleted or purified, was calculated to be equivalent to that contained in 50×10^6 total splenocytes after analysis of their frequency in the following splenocytes: 25×10^6 (T cells), 18×10^6 (CD8⁺ T cells), and 12×10^6 (CD4⁺ T cells).

CD45RC^{high} and CD45RC^{low} CD8⁺ T cells were first purified from total splenocytes after nylon wool adherence and depletion with a cocktail of anti-CD4, anti-CD45R, and anti-CD11b/c reactive mAbs using magnetic beads. Purified CD8⁺ T cells were then incubated with FITC-labeled anti-CD45RC and PE-labeled anti-CD8 α mAbs and sorted using FACSARIA (BD). Purity of sorted populations was systematically greater than 99%.

Flow cytometry. Cells were stained with the following mAbs: anti-TCR $\alpha\beta$ (R73, Alexa Fluor 647-conjugated), anti-CD8 α (OX8, PE-conjugated), anti-CD4 (W3.25, PE-conjugated), anti-CD45RC (OX22, FITC-conjugated), anti-CD28 (JJ319, biotin-labeled), anti-CD103 (OX62, biotin-labeled), anti-CD62L (OX85, biotin-labeled), anti-OX40 (OX40, biotin-labeled), anti-MHC II (OX6, biotin-labeled), and anti-CD25 (OX39, biotin-labeled). All biotin-labeled mAbs were visualized using avidin-PerCP.Cy5.5. A FACSCalibur cytofluorimeter (BD Biosciences) was used to measure fluorescence, and data were analyzed using CellQuest software (version 4.0.2; BD Biosciences).

Immunofluorescence. For immunofluorescence studies of IDO expression, cryostat sections from grafts were thawed, fixed in acetone (10 minutes at room temperature), and incubated (overnight at 4°C, 1.5 μ g/ml) with a polyclonal rabbit anti-IPO Ab produced by us against rat IDO peptides (47), followed by a FITC-conjugated anti-rabbit Ab. An anti-CD31 mAb (an endothelial cell marker; Serotec) was used at 5 μ g/ml, followed by an Alexa Fluor 568-conjugated anti-mouse Ab. IFN- γ was detected using a FITC-conjugated mAb (DB1, 5 mg/ml), and CD8⁺ cells were detected using a biotin-conjugated anti-CD8 α mAb (5 mg/ml) and Alexa Fluor 568-conjugated avidin. Sections were mounted in ProLong AntiFade Kit



(Molecular Probes) and analyzed by confocal microscopy (Leica TCS-SP1). The green and red emissions were collected using 2 photomultiplier tubes. Grayscale digital images were visualized with a 24-bit imaging system using Leica's TCS-NT software.

Intracellular cytokine staining. Splenocytes were harvested and immediately restimulated for 7 hours using phorbol 12-myristate 13-acetate (50 ng/ml, Sigma-Aldrich) and ionomycin (1 µg/ml, Sigma-Aldrich) in the presence of brefeldin A (5 µg/ml) for the last 4 hours. Cells were then fixed in 2% paraformaldehyde and incubated with PBS/0.2% FCS/0.5% saponin for 10 minutes. After 2 washes in PBS/0.2% FCS/0.1% saponin, cells were incubated with isotype controls or FITC-labeled anti-rat IFN-γ mAb, anti-IL-10 (clone A5-4; BD Pharmingen), anti-IL-13 (clone 12G5-IE4; Biosource International), anti-IL-4 (clone OX-81; BD Biosciences – Pharmingen), and anti-TGF-β1 (clone 2G7, kindly provided by K. Melief, Academisch Ziekenhuis, Leiden, The Netherlands, at 5 µg/ml for 30 minutes. After 2 washes with PBS/0.2% FCS/0.1% saponin and 1 wash with PBS/2% FCS/0.2% azide, cells were fixed with 2% paraformaldehyde.

Quantitative RT-PCR. Messenger RNA transcript analysis was performed by quantitative RT-PCR. Total RNA was isolated using TRIzol (Invitrogen). Ten micrograms of RNA were treated with DNase and reverse transcribed using an MMLV Reverse-Transcriptase kit (Invitrogen). Quantitative RT-PCR was performed with a ABI PRISM 7700 Sequence Detection System using Complete Power SYBR Green master mix 2 (Applied Biosystems). The sequences of primer pairs for HPRT, TGF-β1, IFN-γ, IL-10 (48), and HO-1 (46) have been described previously, and the other primer sequences used are listed in Supplemental Table 1. The PCR and quantification methods, which have been previously described (46), were used after normalization of sequences to HPRT values.

TCR repertoire analysis. For quantitative analysis, cDNA were amplified by PCR using a Cβ primer and the 21 specific primers described previously (13) by quantitative RT-PCR. Data were expressed as the ratio of Vβ transcripts levels to HPRT. For the TCR Vβ CDR3 length distribution qualitative analysis, amplification products were used for an elongation reaction using a dye-labeled Cβ primer, then heat denatured, loaded onto a 6% acrylamide-8M urea gel, and electrophoresed using an Applied Biosystems 377A DNA sequencer. The Immunoscope software (version 3.03; Institut

Pasteur) resolved the raw data of DNA sequencing gel into sets of peaks separated by 3 nucleotides, including size, area of peaks representing the TCR-CD3 length distribution profiles, and alteration of distribution.

Treatment with 1-MT and analysis of IDO expression. 1-MT (Sigma-Aldrich) was prepared daily and administered by gavage at 0.2 g/kg twice daily as previously described (49). IDO expression was analyzed by Western blot using an anti-rat IDO rabbit antibody and by measuring kynurenine in culture medium (47).

Culture of ECs and CD8⁺CD45RC^{low} T cells. ECs of LEW.1W or LEW.1A origin were isolated and plated into 12-well plates (5 × 10⁵ cells/well), and after overnight culture, CD8⁺CD45RC^{low} T cells from CD40lg-treated or adoptively transferred LEW.1A recipients were added (4 × 10⁶ cells/well). After 2 days of culture, supernatants were harvested, lymphocytes were discarded, and kynurenines were analyzed. Adherent ECs were washed several times and lysed for RT-PCR analysis of IDO mRNA.

Statistics. Statistical significance was evaluated using the 2-tailed Student's *t* test for 2 groups and the Kruskal-Wallis test followed by a Dunn's post-hoc test for more than 2 groups. Graft survival was analyzed by Kaplan-Meier log-rank test. *P* values less than or equal to 0.05 were considered significant.

Acknowledgments

We thank the Vector Core of the University Hospital of Nantes, which is supported by the Association Française Contre les Myopathies, for producing the adenoviral vectors. We thank Emanuel Merieau, Bernard Martinet, Helga Smit, and Séverine Remy for technical assistance. We thank the Fondation Progreffe for financial support and Crédit Agricole for the donation of the FACSARIA.

Received for publication April 12, 2006, and accepted in revised form January 16, 2007.

Address correspondence to: Ignacio Anegón, ITERT-INSERM U643, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes, France. Phone: 33-240-08-74-15; Fax: 33-240-08-74-11; E-mail: Ignacio.Anegon@univ-nantes.fr.

1. Waldmann, H., and Cobbold, S. 2004. Exploiting tolerance processes in transplantation. *Science*. **305**:209–212.
2. Wood, K.J., and Sakaguchi, S. 2003. Regulatory T cells in transplantation tolerance. *Nat. Rev. Immunol.* **3**:199–210.
3. Xystrakis, E., et al. 2004. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. *Blood*. **104**:3294–3301.
4. Liu, J., et al. 2004. Rat CD8⁺FOXP3⁺T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. *Transpl. Immunol.* **13**:239–247.
5. Zhou, J., Carr, R.I., Liwski, R.S., Stadnyk, A.W., and Lee, T.D. 2001. Oral exposure to alloantigen generates intragraft CD8⁺ regulatory cells. *J. Immunol.* **167**:107–113.
6. Jiang, H., and Chess, L. 2000. The specific regulation of immune responses by CD8⁺ T cells restricted by the MHC class Ib molecule, Qa-1. *Annu. Rev. Immunol.* **18**:185–216.
7. Dhodapkar, M.V., and Steinman, R.M. 2002. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. *Blood*. **100**:174–177.
8. Seo, S.K., et al. 2004. 4-1BB-mediated immunotherapy of rheumatoid arthritis. *Nat. Med.* **10**:1088–1094.
9. Bisikirska, B., Colgan, J., Luban, J., Bluestone, J.A., and Herold, K.C. 2005. TCR stimulation with modified anti-CD3 mAb expands CD8⁺ T cell population and induces CD8⁺CD25⁺ Tregs. *J. Clin. Invest.* **115**:2904–2913. doi:10.1172/JCI23961.
10. Balashov, K.E., Khoury, S.J., Hafner, D.A., and Weiner, H.L. 1995. Inhibition of T cell responses by activated human CD8⁺ T cells is mediated by interferon-γ and is defective in chronic progressive multiple sclerosis. *J. Clin. Invest.* **95**:2711–2719.
11. Chang, C., et al. 2002. Tolerization of dendritic cells by T cells: the crucial role of inhibitory ILT3 and ILT4. *Nat. Immunol.* **3**:237–243.
12. Najafian, N., et al. 2003. Regulatory functions of CD8⁺CD28[−] T cells in an autoimmune disease model. *J. Clin. Invest.* **112**:1037–1048. doi:10.1172/JCI200317935.
13. Douillard, P., et al. 1996. Donor-specific blood transfusion induced tolerance in adult rats with a dominant TcR-Vb rearrangement in heart allografts. *J. Immunol.* **157**:1250–1260.
14. Oluwole, S.F., Ng, A.K., Reemtsma, K., and Hardy, M.A. 1989. The mechanism of the induction of immunologic unresponsiveness to rat cardiac allografts by recipient pretreatment with donor lymphocyte subsets. *Transplantation*. **48**:281–288.
15. Onodera, K.L., et al. 1999. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. *Transplantation*. **68**:288–293.
16. Kataoka, M., Margenthaler, J.A., Ku, G., and Flye, M.W. 2003. Development of infectious tolerance after donor-specific transfusion and rat heart transplantation. *J. Immunol.* **171**:204–211.
17. Larsen, C.P., et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. *Nature*. **381**:434–438.
18. Adams, A.B., et al. 2005. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. *J. Immunol.* **174**:542–550.
19. Guillot, C., et al. 2002. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40lg results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. *J. Immunol.* **168**:1600–1609.
20. Quezada, S.A., Jarvinen, L.Z., Lind, E.F., and Noelle, R.J. 2004. CD40/CD154 interactions at the interface of tolerance and immunity. *Annu. Rev. Immunol.* **22**:307–328.
21. Honey, N.J., Cobbold, S., and Waldmann, H. 1999. CD40 ligand blockade induces CD4⁺ T cell tolerance and linked suppression. *J. Immunol.* **163**:4805–4810.
22. Monk, N.J., et al. 2003. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. *Nat. Med.* **9**:1275–1280.
23. Blair, P.J., et al. 2000. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response



- that results in secretion of immunomodulatory cytokines and apoptosis. *J. Exp. Med.* **191**:651–660.
24. Albert, M., Jegathesan, M., and Darnell, R. 2001. Dendritic cell maturation is required for the cross-tolerization of CD8+ cells. *Nat. Immunol.* **2**:1010–1017.
25. Grohmann, U., et al. 2001. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. *J. Immunol.* **166**:277–283.
26. Martin, E., O'Sullivan, B., Low, P., and Thomas, R. 2003. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. *Immunity.* **18**:155–167.
27. Homann, D., et al. 2002. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. *Immunity.* **16**:403–415.
28. Mellor, A.L., and Munn, D.H. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat. Rev. Immunol.* **4**:762–774.
29. Grohmann, U., et al. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. *Nat. Immunol.* **3**:1097–1101.
30. Graca, L., Honey, K., Adams, E., Cobbold, S., and Waldmann, H. 2000. Anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. *J. Immunol.* **165**:4783–4786.
31. Nomura, M., et al. 2002. Induction of donor-specific tolerance by adenovirus-mediated CD40Ig gene therapy in rat liver transplantation. *Transplantation.* **73**:1403–1410.
32. Gregori, S., et al. 2001. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. *J. Immunol.* **167**:1945–1953.
33. Chiffolleau, E., et al. 2002. Role for thymic and splenic regulatory CD4+ T cells induced by donor dendritic cells in allograft tolerance by LF15-0195 treatment. *J. Immunol.* **168**:5058–5069.
34. Konieczny, B.T., et al. 1998. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. *J. Immunol.* **160**:2059–2064.
35. Sawitzki, B., et al. 2005. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. *J. Exp. Med.* **201**:1925–1935.
36. Tellides, G., et al. 2000. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. *Nature.* **403**:207–211.
37. Shirasugi, N., et al. 2002. Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. *J. Immunol.* **169**:2677–2684.
38. Yamashita, K., et al. 2006. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. *FASEB J.* **20**:776–778.
39. Munn, D.H., et al. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. *Immunity.* **22**:633–642.
40. Beutelspacher, S.C., et al. 2006. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. *Am. J. Transplant.* **6**:1320–1330.
41. Munn, D.H., and Mellor, A.L. 2004. IDO and tolerance to tumors. *Trends Mol. Med.* **10**:15–18.
42. Lee, I., et al. 2005. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. *J. Exp. Med.* **201**:1037–1044.
43. Chen, Z., Herman, A.E., Matos, M., Mathis, D., and Benoist, C. 2005. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. *J. Exp. Med.* **202**:1387–1397.
44. Waldmann, H., et al. 2004. Regulatory T cells and organ transplantation. *Semin. Immunol.* **16**:119–126.
45. Huse, M., Lillemeier, B.F., Kuhns, M.S., Chen, D.S., and Davis, M.M. 2006. T cells use two directionally distinct pathways for cytokine secretion. *Nat. Immunol.* **7**:247–255.
46. Braudeau, C., et al. 2004. Induction of long-term cardiac allograft survival by heme oxygenase-1 gene transfer. *Gene Ther.* **11**:701–710.
47. Hill, M., et al. 2005. Heme oxygenase-1 inhibits rat and human breast cancer cells proliferation: mutual cross-inhibition with indoleamine 2,3-dioxygenase. *FASEB J.* **19**:1957–1968.
48. Guillot, C., et al. 2000. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. *J. Immunol.* **164**:5258–5268.
49. Haspot, F., et al. 2005. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. *Am. J. Transplant.* **5**:2339–2348.